EichorEICHOR
Study identifier: NCT06963034 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: Recruiting

NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

Condition: Schizophrenia  ·  Sponsor: Neurocrine Biosciences

PhasePhase 3
Planned participants284
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNoCheck eligibility criteria ↓
Where21 locations

Interested? Contact the study team ↓

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

This description comes directly from the study's public registry record.

Talk to the study team

Neurocrine Medical Information Call Center  ·  877-641-3461  ·  medinfo@neurocrine.com

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Key Inclusion Criteria: * Participant has a primary diagnosis of schizophrenia * Participant is experiencing an acute exacerbation or relapse of symptoms and currently warrants hospitalization. * Participants taking prohibited medications, including antipsychotics, must discontinue before study participation * Participant is willing and able to remain in an inpatient setting for the study duration, follow instructions, and comply with the protocol requirements Key Exclusion Criteria: * Participant has known hypersensitivity to any component of the formulation of NBI-1117568. * Participant has an unstable or poorly controlled medical condition or chronic disease * Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others * Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening * Participant has a positive alcohol test or drug screen for disallowed substances * Participants have a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements. Note: Other protocol-specified inclusion/exclusion criteria may apply.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (21)

Neurocrine Clinical SiteBryant, Arkansas, United StatesRecruiting
Neurocrine Clinical SiteLittle Rock, Arkansas, United StatesRecruiting
Neurocrine Clinical SiteAnaheim, California, United StatesRecruiting
Neurocrine Clinical SitePico Rivera, California, United StatesRecruiting
Neurocrine Clinical SiteSan Diego, California, United StatesRecruiting
Neurocrine Clinical SiteSherman Oaks, California, United StatesRecruiting
Neurocrine Clinical SiteTorrance, California, United StatesRecruiting
Neurocrine Clinical SiteHollywood, Florida, United StatesRecruiting
Neurocrine Clinical SiteMiami Lakes, Florida, United StatesRecruiting
Neurocrine Clinical SiteAtlanta, Georgia, United StatesRecruiting
Neurocrine Clinical SiteDecatur, Georgia, United StatesRecruiting
Neurocrine Clinical SiteSnellville, Georgia, United StatesRecruiting

+ 9 more locations — full list on the registry record.

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

BryantLittle RockAnaheimPico Rivera

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →